Ozempic vs Wegovy vs Mounjaro: What's the Difference

If you've been researching weight loss medications, you've probably seen the names Ozempic, Wegovy, and Mounjaro used almost interchangeably in headlines and social media posts. They're all injectable medications that help with weight loss, and they're all in the same general class of drugs. But they're not the same medication, and the differences matter.

This guide breaks down how these three medications actually compare, including what they do in your body, how effective they are, what the side effects look like, and what they cost.

The Basics: What Each Medication Is

Let's start with the fundamentals. These medications fall into two groups based on their active ingredient.

Semaglutide medications (Ozempic and Wegovy): Both contain the same active ingredient, semaglutide, which is a GLP-1 receptor agonist. The difference is the approved use and dosing. Ozempic is FDA-approved for type 2 diabetes management at doses up to 2 mg weekly. Wegovy is FDA-approved for chronic weight management at a higher dose of 2.4 mg weekly. Same molecule, different dose, different label.

Tirzepatide medications (Mounjaro and Zepbound): Mounjaro contains tirzepatide, which is a dual GIP/GLP-1 receptor agonist. It was originally approved for type 2 diabetes. Zepbound is the same molecule, approved specifically for weight loss. For this article, we'll focus on Mounjaro since it's the more widely recognized name, but the same information applies to Zepbound.

How They Work: One Hormone vs. Two

This is the most important difference between these medications, and it's worth understanding.

Semaglutide (Ozempic/Wegovy) mimics a single gut hormone called GLP-1 (glucagon-like peptide-1). When you eat, your body naturally releases GLP-1, which signals your brain that you're full, slows stomach emptying so you stay satisfied longer, and triggers insulin release to manage blood sugar. Semaglutide amplifies all of these effects.

Tirzepatide (Mounjaro/Zepbound) mimics two gut hormones: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP has its own effects on appetite, fat metabolism, and insulin sensitivity. By activating both pathways simultaneously, tirzepatide appears to produce a stronger overall metabolic effect.

Think of it this way: semaglutide pulls one lever to reduce appetite and improve metabolism. Tirzepatide pulls two levers at once. That doesn't automatically make tirzepatide "better" for every person, but it does help explain why the clinical trial results differ.

Effectiveness: What the Clinical Trials Show

Both medications have been studied in large, rigorous clinical trials. Here's how the results compare.

Semaglutide (STEP trials): The STEP 1 trial found that participants taking semaglutide 2.4 mg (the Wegovy dose) lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. For a 200-pound person, that's roughly 30 pounds.

Tirzepatide (SURMOUNT trials): The SURMOUNT-1 trial found that participants on the highest dose of tirzepatide (15 mg) lost an average of 20.9% of their body weight over 72 weeks. At the middle dose (10 mg), the average was 19.5%. At the lowest dose (5 mg), it was 15.0%. For a 200-pound person, the highest dose translates to roughly 42 pounds.

These are averages. Individual results vary significantly. Some people respond better to semaglutide, and others respond better to tirzepatide. Your genetics, metabolic profile, starting weight, and adherence to lifestyle changes all play a role.

It's also worth noting that the trials had slightly different durations and study populations, so a direct head-to-head comparison isn't perfectly clean. However, the weight loss difference is consistent enough that most clinicians consider tirzepatide to have a modest edge in average effectiveness.

Side Effects: What to Expect

The side effect profiles of these medications are similar, since they share the GLP-1 mechanism. The most common side effects are gastrointestinal.

Nausea is the most frequently reported side effect for both. It tends to be worst during the first few weeks and during dose increases, then improves as your body adjusts. Roughly 25-44% of patients experience nausea at some point during treatment.

Other GI symptoms include vomiting, diarrhea, constipation, and abdominal discomfort. Again, these are most common early in treatment and during titration.

Less common but notable side effects include gallbladder problems, changes in taste, fatigue, dizziness, and injection site reactions. Pancreatitis is a rare but serious risk with both medication classes.

In general, the GI side effects of tirzepatide and semaglutide appear comparable in clinical trials. Some patients tolerate one better than the other, which is one reason your clinician may recommend trying a different medication if side effects are problematic with your first choice.

Dosing and Titration

All three medications follow a gradual titration schedule, meaning you start at a low dose and increase over time. This approach minimizes side effects and helps your body adjust.

Wegovy (semaglutide for weight loss) starts at 0.25 mg weekly and increases monthly over about 16-20 weeks until reaching the maintenance dose of 2.4 mg.

Ozempic (semaglutide for diabetes) follows a similar pattern, typically titrating up to 1 mg or 2 mg depending on blood sugar control.

Mounjaro (tirzepatide) starts at 2.5 mg weekly and increases every 4 weeks. The maintenance dose ranges from 5 mg to 15 mg, depending on your response and tolerability.

With all of these medications, rushing the titration increases the risk of side effects. Patience during the ramp-up phase pays off in the long run.

Cost and Insurance Coverage

Cost is a significant factor for most people, and pricing for these medications can be steep without insurance coverage.

The list price for Wegovy and Mounjaro/Zepbound runs roughly $1,000 to $1,300 per month without insurance. Ozempic is in a similar range. Actual out-of-pocket costs vary widely depending on your insurance plan, manufacturer coupons, and pharmacy.

Insurance coverage has been expanding but remains inconsistent. Many plans cover these medications for type 2 diabetes but not for weight loss. Some plans have added weight loss coverage, especially for employer-sponsored plans, but prior authorization and step therapy requirements are common.

Which One Is Right for You?

There's no universal "best" option among these medications. The right choice depends on several factors: whether you have type 2 diabetes (which affects which medications are indicated and covered), your insurance formulary, your tolerance for side effects, your weight loss goals, and your clinician's recommendation based on your full health picture.

Some general patterns: if you have type 2 diabetes and want weight loss benefits, either Ozempic or Mounjaro may be appropriate. If your primary goal is weight management without diabetes, Wegovy or Zepbound are the specifically indicated options. If you've tried semaglutide and plateaued or had tolerability issues, switching to tirzepatide (or vice versa) is a reasonable next step.

The most important thing is working with a clinician who understands these medications, can evaluate your individual situation, and can help you navigate the practical considerations of access and cost.

If you're considering a GLP-1 medication and want to understand which option makes the most sense for you, Embirwell's weight loss assessment is a good starting point. It takes 60 seconds and connects you with a clinician who can walk you through the options based on your specific health profile.